Clinical Trial Update: The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer

View source ↗

Summary

Clinical trial update on personalized ctDNA-based minimal residual disease (MRD) assessment in cervical cancer, sponsored by Geneplus-Beijing Co. Ltd; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Ovarian Cancer

Snippet

Sponsor: Geneplus-Beijing Co. Ltd. | Conditions: Ovarian Cancer | Status: NOT_YET_RECRUITING